Does procalcitonin have a role in the pathogenesis of nasal polyp?
The aim of this study is to investigate serum and tissue procalcitonin (PCT) levels in patients with nasal polyps.
The study was designed to be prospectively controlled and included 26 patients chronic rhinosinusitis with nasal polyp (CRSwNP) endoscopically diagnosed and as a control group 25 chronic rhinosinusitis without nasal polyp (CRSsNP). NP specimens, nasal mucosal tissue and venous blood samples of both groups were collected and PCT levels determined by Elisa method. The results were compared statistically.
Serum PCT values were 1319.5 pg/mL in the NP group and 818.8 pg/mL in the control group. The difference between the groups was statistically significant (p = 0.0001). In the NP group, the average PCT value of the polyp tissue was 1521.5 pg/gr, while the mean PCT value of the control group in the nasal mucosa was 414.6 pg/gr. There was a statistically significant difference between the groups (p = 0.0001). The tissue cut-off value of PCT 750 was significant [area under curve 0.940 (0.863–1.00)]. Serum PCT 950 cut-off value was significant [area under curve 0.860 (0.748–0.972)] activity (CI: 95%).
This is the first study of its kind to objectively examine PCT in the polyp and serum of CRSwNP patients. PCT may serve as a diagnostic biomarker in nasal polyps.
KeywordsNasal polyps Procalcitonin Pathogenesis Sinusitis
We appreciate all the authors who have made efforts in the whole program, and also thank all the researchers of the primary studies. We would like to thank Ertan Koç for his contributions as all authors in this study.
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Sreeparvathı A. Kalyanikuttyamma LK, Kumar M, Sreekumar N, Veerasigamani N (2017) Significance of blood eosinophil count in patients with chronic rhinosinusitis with nasal polyposis. J Clin Diagn Res 11(2): MC08–MC11Google Scholar
- 6.Davidsson A, Danielsen A, Viale G, Olofsson J, Dell’Orto P, Pellegrini C, Karlsson MG, Hellquist HB (1996) Positive identification in situ of mRNA expression of IL-6, and IL-12, and the chemotactic cytokine RANTES in patients with chronic sinusitis and polypoid disease. Clinical relevance and relation to allergy. Acta Otolaryngol 116(4):604–610CrossRefGoogle Scholar
- 9.Szabó K, Kiricsi Á, Révész M, Vóna I, Szabó Z, Bella Z, Polyánka H, Kadocsa E, Kemény L, Széll M, Hirschberg A (2013) The – 308 G> A SNP of TNFα is a factor predisposing to chronic rhinosinusitis associated with nasal polyposis in aspirin-sensitive Hungarian individuals: conclusions of a genetic study with multiple stratifications. Int Immunol 25(6):383–388CrossRefGoogle Scholar
- 12.Samsudin I, Vasikaran SD (2017) Clinical utility and measurement of procalcitonin. Clin Biochem Rev 38(2):59–68Google Scholar
- 13.Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P (2018) Efficacy and safety of procalcitonin guidance in patients with suspected or confirmed sepsis: a systematic review and meta-analysis. Crit Care Med 46(5):691–698CrossRefGoogle Scholar
- 17.Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, Bohuon C (1994) Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 79(6):1605–1608Google Scholar